Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Dincer Firat"'
Autor:
Yavuz Ozisik, Dincer Firat, Nilüfer Güler, Ibrahim Gullu, Ayse Kars, Ibrahim Barista, Semra Dündar, Emin Kansu, Nurullah Zengin, Oktay Özdemir
Publikováno v:
Hematology (Amsterdam, Netherlands). 2(2)
Staging systems are essential for understanding disease, in predicting the outcome, and therapeutic decision making in any tumor as well as chronic lymphocytic leukemia (CLL). In this study, we compared the clinical correlation of the Rai and Binet c
Autor:
Ibraham Gullu, Suayib Yalcin, Ibrahim Barista, Kadri Altundag, Mutlu Hayran, Nilüfer Güler, Emin Kansu, Nurallah Zengin, Gülten Tekuzman, Esmen Baltali, Ayse Kars, Alev Turker, Yavuz Ozisik, Ismail Celik, Dincer Firat
Publikováno v:
Scopus-Elsevier
The aim of this study was to evaluate the response characteristics of vincristine, adriamycin and dexamethasone (VAD) as a first-line chemotherapy and to determine the efficacy of maintenance alpha-interferon (alpha-IFN) in multiple myeloma (MM). Bet
Autor:
Nilüfer Güler, Esmen Baltali, Ayse Kars, Aysegul Uner, Ibrahim Barista, Suayib Yalcin, Ismail Celik, Kadri Altundag, Ibrahim Gullu, Gülten Tekuzman, Alev Turker, Yavuz Ozisik, Dincer Firat, Nurullah Zengin
Publikováno v:
Journal of Surgical Oncology. 73:12-16
Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was admin
Autor:
Şevket Ruacan, Yavuz Ozisik, Ibtisam Lale Atahan, Dincer Firat, Ibrahim Gullu, Gülten Tekuzman, Ibrahim Barista, Nilüfer Güler, Esmen Baltali, Ayse Kars
Publikováno v:
Acta Oncologica. 39:135-139
This study was undertaken to define the natural history and treatment results of patients with primary breast non-Hodgkin's lymphoma (NHL). Twelve female patients who had been followed at Hacettepe University Hospital between 1973 and 1997 were retro
Autor:
Charles D. Sherman, Kenneth C. Calman, Sandor Eckhardt, Ismail Elsebai, Dincer Firat, Dieter K. Hossfeld, Jean-Pierre Paunier, Bruno Salvadori
The continuing success of the VICC's Manual of Clinical Oncology and the continuing refinement of our educational objectives in cancer designed for graduating medical students and young practitioners, cou pled with significant additional knowledge
Autor:
Mustafa Benekli, Ibrahim Gullu, Gülten Tekuzman, Dincer Firat, Mutlu Hayran, Savaş Mc, G. Hasçelik
Publikováno v:
British Journal of Cancer
Scopus-Elsevier
Scopus-Elsevier
A diversity of adhesive interactions occur between the cancer cell and host extracellular matrix which potentiate neoplastic expansion and metastatic dissemination. In miscellaneous malignant diseases, tumour progression has been observed to be assoc
Autor:
Dincer Firat, Serafettin Kirazli, Esmen Baltali, Gülten Tekuzman, Ozgur Ozyilkan, Oktay Özdemir
Publikováno v:
Tumori Journal. 84:364-367
Aims and backgroundDisorders of hemostasis in patients with malignancies are based on several mechanisms, such as ability of the tumor to alter the coagulation system by producing blood clotting factors or decreasing their inhibitors by increasing fi
Publikováno v:
American Journal of Clinical Oncology. 21:185-188
The efficacy of diflunisal in cancer pain was evaluated and compared with dipyrone. Diflunisal was given at the dosage of 500 mg perorally twice a day, and dipyrone was given at the dosage of 500 mg perorally three times a day. Duration of each treat
Autor:
Görgun Akpek, Yener Koc, Esmen Baltali, Nilüfer Güler, Ayse Kars, Emin Kansu, Dincer Firat, Ibrahim Gullu, Yavuz Ozisik, Gülten Tekuzman, Ibrahim Barista
Publikováno v:
Cancer Investigation. 16:355-365
Two consecutive phase II clinical studies were designed to evaluate the efficacy and safety of bolus and continuous infusion (CI) mitoxantrone (MTZ) in 39 patients with newly diagnosed acute lymphocytic leukemia (ALL). MTZ was used as part of the cla
Autor:
Mustafa Benekli, Esmen Baltali, Ayse Kars, Ibrahim Gullu, Ibrahim Barista, Gülten Tekuzman, Dincer Firat, Ismail Celik, Nilüfer Güler, Sedat Kiraz
Publikováno v:
Scopus-Elsevier
Aims and background Ifosfamide is an active alkylating agent in the treatment of breast cancer, as a first-line therapy and in advanced disease. Since the combination of etoposide with an alkylating agent produces a synergistic and tolerable activity